Objective:

To report the FDA approval of NEREUS (tradipitant) for the prevention of motion-induced vomiting in adults.

Approach:

Key Findings:

• In Motion Syros (n = 365), vomiting occurred in 18% to 20% of patients receiving tradipitant versus 44% receiving placebo.
• In Motion Serifos (n = 316), vomiting rates ranged from 10% to 18% with tradipitant versus 38% with placebo.
• Risk reductions of 50% to 70% were observed across studies.
• Tradipitant showed a favorable safety profile with common adverse reactions including somnolence and fatigue.

Interpretation:

The approval of tradipitant marks a significant advancement in the treatment of motion sickness, providing a new option for patients who have limited success with existing therapies.

Limitations:

• Safety and effectiveness have not been established in pediatric patients.
• Use is cautioned in patients with severe renal or hepatic impairment.

Conclusion:

Tradipitant offers a novel therapeutic approach to motion sickness, leveraging modern neuropharmacology to improve patient outcomes.

Sources:

• Vanda Pharmaceuticals
Source

Based on findings from:

NK-1 Drug Fills Motion Sickness Gap

Kerri Miller. MDSpire News, 2026.

https://news.mdspire.com/otolaryngology/articles/nk1-drug-fills-motion-sickness-gap/

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.